Company
Headquarters: Mississauga, ON, Canada
Employees: 146
CEO: Dr. Arun Swarup Menawat MBA, Ph.D.
C$312.3 Million
CAD as of Jan. 1, 2025
US$217.1 Million
Company | Market Cap (USD) |
---|---|
Abbott | $213.72 B |
Stryker | $150.01 B |
Boston Scientific Corporation | $149.80 B |
Medtronic | $114.44 B |
Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $47.37 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Last Financial Reports Date | Dec. 31, 2023 |
Revenue TTM | C$9.8 M |
EBITDA | C$-38,078,835 |
Gross Profit TTM | C$4.4 M |
Profit Margin | 60.87% |
Operating Margin | -437.13% |
Quarterly Revenue Growth | 59.80% |
Profound Medical Corp. has the following listings and related stock indices.
Stock: TSX: PRN wb_incandescent
Stock: NASDAQ: PROF wb_incandescent